{"id":6619,"date":"2021-03-25T07:44:07","date_gmt":"2021-03-25T06:44:07","guid":{"rendered":"http:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/03\/Enterome-Receives-FDA-IND-Clearance-for-EO2463-an-\u2018OncoMimic\u2019-based-Immunotherapy-Targeting-Liquid-Tumors-_-ENTEROME-24-03.pdf"},"modified":"2021-03-25T07:44:07","modified_gmt":"2021-03-25T06:44:07","slug":"enterome-receives-fda-ind-clearance-for-eo2463-an-oncomimic-based-immunotherapy-targeting-liquid-tumors-_-enterome-24-03","status":"inherit","type":"attachment","link":"https:\/\/www.seventure.fr\/en\/enterome-receives-fda-ind-clearance-for-eo2463-an-oncomimic-based-immunotherapy-targeting-liquid-tumors\/enterome-receives-fda-ind-clearance-for-eo2463-an-oncomimic-based-immunotherapy-targeting-liquid-tumors-_-enterome-24-03\/","title":{"rendered":"Enterome Receives FDA IND Clearance for EO2463, an \u2018OncoMimic\u2019 based Immunotherapy Targeting Liquid Tumors _ ENTEROME 24 03"},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false},"class_list":["post-6619","attachment","type-attachment","status-inherit","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.0 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Enterome Receives FDA IND Clearance for EO2463, an \u2018OncoMimic\u2019 based Immunotherapy Targeting Liquid Tumors _ ENTEROME 24 03 | Seventure<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/03\/Enterome-Receives-FDA-IND-Clearance-for-EO2463-an-\u2018OncoMimic\u2019-based-Immunotherapy-Targeting-Liquid-Tumors-_-ENTEROME-24-03.pdf\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/03\/Enterome-Receives-FDA-IND-Clearance-for-EO2463-an-\u2018OncoMimic\u2019-based-Immunotherapy-Targeting-Liquid-Tumors-_-ENTEROME-24-03.pdf\",\"url\":\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/03\/Enterome-Receives-FDA-IND-Clearance-for-EO2463-an-\u2018OncoMimic\u2019-based-Immunotherapy-Targeting-Liquid-Tumors-_-ENTEROME-24-03.pdf\",\"name\":\"Enterome Receives FDA IND Clearance for EO2463, an \u2018OncoMimic\u2019 based Immunotherapy Targeting Liquid Tumors _ ENTEROME 24 03 | Seventure\",\"isPartOf\":{\"@id\":\"https:\/\/www.seventure.fr\/en\/#website\"},\"datePublished\":\"2021-03-25T06:44:07+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/03\/Enterome-Receives-FDA-IND-Clearance-for-EO2463-an-\u2018OncoMimic\u2019-based-Immunotherapy-Targeting-Liquid-Tumors-_-ENTEROME-24-03.pdf#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/03\/Enterome-Receives-FDA-IND-Clearance-for-EO2463-an-\u2018OncoMimic\u2019-based-Immunotherapy-Targeting-Liquid-Tumors-_-ENTEROME-24-03.pdf\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/03\/Enterome-Receives-FDA-IND-Clearance-for-EO2463-an-\u2018OncoMimic\u2019-based-Immunotherapy-Targeting-Liquid-Tumors-_-ENTEROME-24-03.pdf#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.seventure.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Enterome Receives FDA IND Clearance for EO2463, an \u2018OncoMimic\u2019 based Immunotherapy Targeting Liquid Tumors\",\"item\":\"https:\/\/www.seventure.fr\/en\/enterome-receives-fda-ind-clearance-for-eo2463-an-oncomimic-based-immunotherapy-targeting-liquid-tumors\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Enterome Receives FDA IND Clearance for EO2463, an \u2018OncoMimic\u2019 based Immunotherapy Targeting Liquid Tumors _ ENTEROME 24 03\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.seventure.fr\/en\/#website\",\"url\":\"https:\/\/www.seventure.fr\/en\/\",\"name\":\"Seventure\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.seventure.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Enterome Receives FDA IND Clearance for EO2463, an \u2018OncoMimic\u2019 based Immunotherapy Targeting Liquid Tumors _ ENTEROME 24 03 | Seventure","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/03\/Enterome-Receives-FDA-IND-Clearance-for-EO2463-an-\u2018OncoMimic\u2019-based-Immunotherapy-Targeting-Liquid-Tumors-_-ENTEROME-24-03.pdf","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/03\/Enterome-Receives-FDA-IND-Clearance-for-EO2463-an-\u2018OncoMimic\u2019-based-Immunotherapy-Targeting-Liquid-Tumors-_-ENTEROME-24-03.pdf","url":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/03\/Enterome-Receives-FDA-IND-Clearance-for-EO2463-an-\u2018OncoMimic\u2019-based-Immunotherapy-Targeting-Liquid-Tumors-_-ENTEROME-24-03.pdf","name":"Enterome Receives FDA IND Clearance for EO2463, an \u2018OncoMimic\u2019 based Immunotherapy Targeting Liquid Tumors _ ENTEROME 24 03 | Seventure","isPartOf":{"@id":"https:\/\/www.seventure.fr\/en\/#website"},"datePublished":"2021-03-25T06:44:07+00:00","breadcrumb":{"@id":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/03\/Enterome-Receives-FDA-IND-Clearance-for-EO2463-an-\u2018OncoMimic\u2019-based-Immunotherapy-Targeting-Liquid-Tumors-_-ENTEROME-24-03.pdf#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/03\/Enterome-Receives-FDA-IND-Clearance-for-EO2463-an-\u2018OncoMimic\u2019-based-Immunotherapy-Targeting-Liquid-Tumors-_-ENTEROME-24-03.pdf"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/03\/Enterome-Receives-FDA-IND-Clearance-for-EO2463-an-\u2018OncoMimic\u2019-based-Immunotherapy-Targeting-Liquid-Tumors-_-ENTEROME-24-03.pdf#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.seventure.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Enterome Receives FDA IND Clearance for EO2463, an \u2018OncoMimic\u2019 based Immunotherapy Targeting Liquid Tumors","item":"https:\/\/www.seventure.fr\/en\/enterome-receives-fda-ind-clearance-for-eo2463-an-oncomimic-based-immunotherapy-targeting-liquid-tumors\/"},{"@type":"ListItem","position":3,"name":"Enterome Receives FDA IND Clearance for EO2463, an \u2018OncoMimic\u2019 based Immunotherapy Targeting Liquid Tumors _ ENTEROME 24 03"}]},{"@type":"WebSite","@id":"https:\/\/www.seventure.fr\/en\/#website","url":"https:\/\/www.seventure.fr\/en\/","name":"Seventure","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.seventure.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"description":{"rendered":"<p class=\"attachment\"><a href='https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/03\/Enterome-Receives-FDA-IND-Clearance-for-EO2463-an-\u2018OncoMimic\u2019-based-Immunotherapy-Targeting-Liquid-Tumors-_-ENTEROME-24-03.pdf'><img loading=\"lazy\" decoding=\"async\" width=\"212\" height=\"300\" src=\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/03\/Enterome-Receives-FDA-IND-Clearance-for-EO2463-an-\u2018OncoMimic\u2019-based-Immunotherapy-Targeting-Liquid-Tumors-_-ENTEROME-24-03-pdf-212x300.jpg\" class=\"attachment-medium size-medium\" alt=\"\" \/><\/a><\/p>\n"},"caption":{"rendered":""},"alt_text":"","media_type":"file","mime_type":"application\/pdf","media_details":{"sizes":{"thumbnail":{"file":"Enterome-Receives-FDA-IND-Clearance-for-EO2463-an-\u2018OncoMimic\u2019-based-Immunotherapy-Targeting-Liquid-Tumors-_-ENTEROME-24-03-pdf-106x150.jpg","width":106,"height":150,"mime_type":"image\/jpeg","source_url":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/03\/Enterome-Receives-FDA-IND-Clearance-for-EO2463-an-\u2018OncoMimic\u2019-based-Immunotherapy-Targeting-Liquid-Tumors-_-ENTEROME-24-03-pdf-106x150.jpg"},"medium":{"file":"Enterome-Receives-FDA-IND-Clearance-for-EO2463-an-\u2018OncoMimic\u2019-based-Immunotherapy-Targeting-Liquid-Tumors-_-ENTEROME-24-03-pdf-212x300.jpg","width":212,"height":300,"mime_type":"image\/jpeg","source_url":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/03\/Enterome-Receives-FDA-IND-Clearance-for-EO2463-an-\u2018OncoMimic\u2019-based-Immunotherapy-Targeting-Liquid-Tumors-_-ENTEROME-24-03-pdf-212x300.jpg"},"large":{"file":"Enterome-Receives-FDA-IND-Clearance-for-EO2463-an-\u2018OncoMimic\u2019-based-Immunotherapy-Targeting-Liquid-Tumors-_-ENTEROME-24-03-pdf-724x1024.jpg","width":724,"height":1024,"mime_type":"image\/jpeg","source_url":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/03\/Enterome-Receives-FDA-IND-Clearance-for-EO2463-an-\u2018OncoMimic\u2019-based-Immunotherapy-Targeting-Liquid-Tumors-_-ENTEROME-24-03-pdf-724x1024.jpg"},"full":{"file":"Enterome-Receives-FDA-IND-Clearance-for-EO2463-an-\u2018OncoMimic\u2019-based-Immunotherapy-Targeting-Liquid-Tumors-_-ENTEROME-24-03-pdf.jpg","width":1058,"height":1497,"mime_type":"application\/pdf","source_url":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/03\/Enterome-Receives-FDA-IND-Clearance-for-EO2463-an-\u2018OncoMimic\u2019-based-Immunotherapy-Targeting-Liquid-Tumors-_-ENTEROME-24-03-pdf.jpg"}}},"post":6618,"source_url":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/03\/Enterome-Receives-FDA-IND-Clearance-for-EO2463-an-\u2018OncoMimic\u2019-based-Immunotherapy-Targeting-Liquid-Tumors-_-ENTEROME-24-03.pdf","_links":{"self":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/media\/6619","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/media"}],"about":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/types\/attachment"}],"author":[{"embeddable":true,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/comments?post=6619"}]}}